Breaking Finance News

Valeant Pharmaceuticals (TSE:VRX) stock price target increased to $28.00, issued a research note today by RBC Capital Markets

Boasting a price of $14.33, Valeant Pharmaceuticals (TSE:VRX) traded -3.53% lower on the day. With the last stock price close down -40.57% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Valeant Pharmaceuticals has recorded a 50-day average of $18.35 and a two hundred day average of $23.89. Volume of trade was down over the average, with 1,037,255 shares of VRX changing hands under the typical 1,430,290

In a report announced on 3/20/2017 RBC Capital Markets upped the price target of Valeant Pharmaceuticals (TSE:VRX) to $28.00 stating a potential upside of 0.95%.

On 3/1/2017, RBC Capital Markets released a statement for Valeant Pharmaceuticals (TSE:VRX) bumped up the target price from $0.00 to $28.00 that suggested an upside of 0.50%.

Performance Chart

Valeant Pharmaceuticals (TSE:VRX)

With a total market value of $0, Valeant Pharmaceuticals has with a one year low of $14.15 and a one year high of $50.18 .

A total of 6 equity analysts have released a research note on VRX. One equity analyst rating the company a strong buy, zero equity analysts rating the company a buy, five equity analysts rating the company a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $25.75.

More About Valeant Pharmaceuticals (TSE:VRX)

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.